DALLAS, July 29, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring pharmaceutical company Metabasis Therapeutics Inc. (Nasdaq:MBRX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Metabasis Therapeutics Inc. (Nasdaq:MBRX) should be of particular interest to other pharmaceutical companies: GlaxoSmithKline plc. (NYSE:GSK), Eli Lilly & Co. (NYSE:LLY), Amgen Inc. (Nasdaq:AMGN) and Genzyme Corp. (Nasdaq:GENZ).
It is available at: http://www.beaconequity.com/i/MBRX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Metabasis Therapeutic Inc. (MBRX) is an emerging pharmaceutical company focused on the development and commercialization of novel drugs for the treatment of metabolic diseases. Its lead drug candidates MB07811 and MB07803, which are developed for the treatment of hyperlipidemia and type II diabetes, respectively, are in phase II clinical trials. The Company's drug candidates in pretrial studies include AMPK and Glucagan antagonist for the treatment of type II diabetes, and TRss agonist for the treatment of hyperlipidemia. The Company maintains collaborative research and development agreements with Roche; Merck & Company; Idenix Pharmaceuticals Inc; Daiichi Sankyo Company Ltd; Valeant Pharmaceuticals International; and Schering Corporation.
In the report, the analyst notes:
"On June 10, the Company announced that its research collaborative with Merck & Company has produced a lead candidate called AMP protein kinase (AMPK) for further preclinical trials. Terms of the agreement include a one-time fee paid by Merck to MBRX of $6 million as a payment for future obligations from milestones and royalty payments.
"In May, MBRX said it had restructured the Company due to difficulties raising additional capital. The Company warned that if it could not raise additional capital in addition to the above-mentioned $6 million, the Company might be forced to file for bankruptcy protection."
To read the entire report visit: http://www.beaconequity.com/i/MBRX
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.